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Abstract
Background: Neuroblastoma patients show heterogeneous clinical courses ranging from life-
threatening progression to spontaneous regression. Recently, gene expression profiles of
neuroblastoma tumours were associated with clinically different phenotypes. However, such data
is still rare for important patient subgroups, such as patients with MYCN non-amplified advanced
stage disease. Prediction of the individual course of disease and optimal therapy selection in this
cohort is challenging. Additional research effort is needed to describe the patterns of gene
expression in this cohort and to identify reliable prognostic markers for this subset of patients.
Methods: We combined gene expression data from two studies in a meta-analysis in order to
investigate differences in gene expression of advanced stage (3 or 4) tumours without MYCN
amplification that show contrasting outcomes (alive or dead) at five years after initial diagnosis. In
addition, a predictive model for outcome was generated. Gene expression profiles from 66 patients
were included from two studies using different microarray platforms.
Results: In the combined data set, 72 genes were identified as differentially expressed by meta-
analysis at a false discovery rate (FDR) of 8.33%. Meta-analysis detected 34 differentially expressed
genes that were not found as significant in either single study. Outcome prediction based on data
of both studies resulted in a predictive accuracy of 77%. Moreover, the genes that were
differentially expressed in subgroups of advanced stage patients without MYCN  amplification
accurately separated MYCN  amplified tumours from low stage tumours without MYCN
amplification.
Conclusion: Our findings support the hypothesis that neuroblastoma consists of two biologically
distinct subgroups that differ by characteristic gene expression patterns, which are associated with
divergent clinical outcome.
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Background
Neuroblastoma is a malignant tumour of the sympathetic
nervous system. Next to brain tumours, it is the most com-
mon solid tumour in children, with 7.5 cases per 100,000
infants [1]. The hallmark of this tumour is its heterogene-
ous clinical behaviour, ranging from life-threatening
tumour progression to spontaneous regression or differ-
entiation to benign ganglioneuroma. To discriminate
these contrasting patterns of clinical behaviour, several
molecular and cytogenetic features, such as amplification
of the MYCN  oncogene or deletion of chromosomal
material from 1p or 11q are currently used in clinical trials
[1,2]. However, the course of intermediate risk patients
with MYCN non-amplified advanced stage disease is still
hard to predict by these markers, and optimal therapy
selection in this cohort remains challenging. Thus, current
neuroblastoma trials may stratify these advanced stage
MYCN  non-amplified patients to either the low-, the
intermediate- or the high-risk group leading to highly dif-
fering treatment approaches [3]. Therefore, additional
research effort is needed to identify reliable prognostic
markers for these subsets of patients [4].
To this end, recent studies applied gene expression profil-
ing to investigate divergent clinical neuroblastoma phe-
notypes [5-8]. These studies have shown that it is possible
to discriminate subtypes of neuroblastomas of diverse
molecular and clinical phenotype by their gene expression
profiles. However, gene expression data for the important
subgroup of MYCN  non-amplified neuroblastoma
patients of advanced stage disease (International Neurob-
lastoma Staging System, INSS Stage 3 or 4,) is still rare,
leading to a high risk of false positive and false negative
findings [9].
In this study, we combined gene-expression data from two
different studies generated by different platforms, since a
combined analysis yields more information than each
individual study [10,11]. Although microarray data gener-
ated by different platforms are not directly comparable,
they can be combined in an integrative analysis, if appro-
priate methods are carefully chosen [12]. We focused on
MYCN non-amplified tumours with advanced INSS stage
3 or 4. We searched for differences in gene expression
between patients with contrasting outcomes (alive or
dead) at five years after initial diagnosis. Differentially
expressed genes were identified and described based on
data of the two largest neuroblastoma gene expression
studies to date [7,8]. In addition, a predictive model (clas-
sifier) for patient outcome was generated and assessed.
Methods
Gene Expression Data
Microarray data by Ohira et al. [7] were downloaded from
the NCBI GEO [13] database (accession number
GSE2283), and microarray data by Oberthuer et al. [8]
were downloaded from the EBI ArrayExpress [14] data-
base (accession number E-TABM-38). For both data sets
normalized expression data were used as published.
The probes of the different microarray platforms were
mapped by a perfect match of their sequences. If an oligo-
nucleotide probe of the platform used by Oberthuer et al.
had a sequence that could be matched to a part of the
GenBank mRNA sequence corresponding to a cDNA
clone probe of the platform used by Ohira et al., both
probes were considered as representing the same tran-
script. For genes represented by several probes on a plat-
form the median expression value of all corresponding
probes was used.
Gene expression profiles of patients were selected from
both studies according to the following criteria: MYCN
non-amplified tumors with advanced INSS stage (3 or 4)
with either a minimum follow-up time of five years after
diagnosis or with fatal outcome of disease. All patients
were grouped according to their outcome status (alive vs.
dead) five years after initial diagnosis. In addition, we ran-
domly selected 40 other patients from both studies
(MYCN amplified stage 3 or 4 tumours, ten of each study;
MYCN non amplified tumours with stages 1, 2 or 4S, ten
of each study). According to their clinical characteristics,
these patients have either a highly aggressive neuroblast-
oma tumour or a tumour with very good prognosis. We
used the microarray data of these tumors to study the
expression of the genes found to be differentially
expressed in our meta-analysis of intermediate risk neu-
roblastomas in patients with either distinct favourable or
unfavourable course of disease.
Identification of significant genes
To detect significant differential expression of a gene
between the two outcome patient groups across studies,
we applied a meta-analysis approach as described by Choi
et al. [10]. The Bioconductor [15] software package Gen-
eMeta was used to perform these calculations.
Moreover, to explore the biological aspects of the signifi-
cant genes, we analysed the associated Gene Ontology
(GO) [16] terms using the GOstat software [17], which
generates statistics of which annotations are overrepre-
sented in a given list of genes.
Classification analysis
A predictive model for the patient outcome status (alive
vs. dead) five years after diagnosis was generated using the
method of nearest shrunken centroids classification [18].
Using only the data of genes represented on both micro-
array platforms (n = 1,271), we applied a methodologyBMC Cancer 2007, 7:89 http://www.biomedcentral.com/1471-2407/7/89
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evaluated by Warnat et al. [11], namely the median rank
scores (MRS), to derive numerically comparable quanti-
ties from the expression values of both platforms used in
the different studies. In total, 36 patients were selected
from both studies as a training set to generate a predictive
model of patient outcome (Additional File 1). The
remaining 30 patients were used as an independent test
set. In addition, samples of the independent test set were
classified according to the clinical markers age at diagno-
sis and INSS stage.
Supplementary information is available at the website of
BMC Cancer.
Results
Gene Expression Data
We focused on data of the two biggest current neuroblas-
toma gene-expression studies from Ohira et al. [7] and
Oberthuer et al. [8]. These studies analysed a total of 136
(Ohira) and 251 patients (Oberthuer). Further neuroblas-
toma gene expression studies by Wei et al. [5] and
Schramm et al. [6] comprised 18 and 4 patients that met
the criteria of our cohort (patients with advanced stage
disease without MYCN-amplification). However, based
on mappings to the Unigene database, the number of
UniGene clusters represented on each of the four microar-
ray platforms used in the studies of Wei et al., Schramm et
al., Ohira et al. and Oberthuer et al. only sums up to 362
UniGene clusters. In addition, the data of Wei et al. is not
available in a public microarray data repository. Thus, we
decided to use only data from the studies of Ohira et al.
and Oberthuer et al.
In the study of Ohira et al. [7] a cDNA microarray plat-
form with 5,430 probes representing 4,204 different Gen-
Bank entries was used. In the study of Oberthuer et al. [8]
an oligonucleotide array with 10,163 probes representing
8,155 UniGene clusters was used. By means of sequence
comparison, we found 1,271 genes that are represented
on both platforms. Applying a minimum follow-up time
of five years after initial diagnosis, gene expression pro-
files of MYCN  non-amplified tumours with advanced
INSS stage (3 or 4) from 66 patients were obtained in total
from both studies (Table 1).
Although risk stratification and treatment strategies of
neuroblastoma are different for a small fraction of
patients [ref. [3] and Additional File 1] between Japan and
Germany, the resulting 5-years overall survival is compa-
rable among the German and Japanese neuroblastoma
risk groups, suggesting that the selected patient cohorts
from both studies [7,8] can be compared in a combined
analysis as performed here.
Identification of significant genes
To detect significant differential expression of a gene
between the two outcome patient groups across studies,
we applied a meta-analysis approach as described by Choi
et al. [10]. Based on a Q statistic it was decided to use a
random effects model in the meta-analysis rather than a
fixed effects model (Additional File 1). Using a random
effects model and a threshold of 2.57 (corresponding to p
= 0.01 of a N(0,1) distribution) for the average effect size
calculated on both data sets, we identified 72 genes which
are significantly differentially expressed between the two
outcome groups at a false discovery rate of 8.33%. A
number of 34 of these were found exclusively in the meta-
analysis of both sets, and not in any single study data-
based analysis applying the same threshold (Table 2).
This finding points to the fact that meta-analyses, due to
an enhanced statistical power, may disclose differentially
expressed genes that are missed by analyses of single study
gene expression data sets.
To visualise the expression of the significant genes, colour
maps were generated showing a hierarchical clustering of
the gene expression values for each study separately (Fig.
1A,B). The samples of the study of Oberthuer et al. (Figure
1A) are grouped into threee main groups, as indicated by
the sample dendrogram generated by hierarchical cluster-
ing. These three groups consist of the following samples
(from left to right): NB412-NB331, NB279-NB025,
NB572-NB250. The two leftmost groups mainly contain
patients with unfavourable outcome, while only seven of
23 patients in these two groups show a favourable out-
come. Of these seven patients, three already had a clinical
event (see following paragraph about clinical courses of
these patients). The third group (NB572-NB250) contains
20 patients, all having a favourable outcome. In the clus-
tering results of Ohira et al., two samples can be identified
that show an expression profile clearly distinct from the
Table 1: Patient characteristics.
Study Oberthuer et al. Ohira et al.
Outcome
F2 7 1 4
UF 16 9
Age
<1a 31 9
>1a 12 14
Stage
31 3 1 3
43 0 1 0
1p
Het 31 n.d.
Im 5 n.d.
Del 6 n.d.
ND 1 n.d.
For the study of Ohira et al. no information about the 1p status was 
available(n.d.: not determined). F: favourable; UF: unfavourable; Het: 
heterozygous; Im: imbalance; Del: deletion; ND: not defined.BMC Cancer 2007, 7:89 http://www.biomedcentral.com/1471-2407/7/89
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Table 2: List of differentially expressed genes.
Symbol Name z score only found in M.A.
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51 kDa -3.98
TP53 Tumor protein p53 (Li-Fraumeni syndrome) -3.54
AHCY S-adenosylhomocysteine hydrolase -3.44
NPM1 Nucleophosmin (nucleolar phosphoprotein B23, numatrin) -3.38 *
CHD1L Chromodomain helicase DNA binding protein 1-like -3.26
CCNB1 Cyclin B1 -3.22
HSPA5 Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) -3.20
SF4 Splicing factor 4 -3.19
CCNA2 Cyclin A2 -3.15
RPS13 Ribosomal protein S13 -3.14 *
E2F1 E2F transcription factor 1 -3.12
FLJ11806 Nuclear protein UKp68 -3.12
RUVBL1 RuvB-like 1 (E. coli) -3.10
CCT5 Chaperonin containing TCP1, subunit 5 (epsilon) -3.05 *
CCT3 Chaperonin containing TCP1, subunit 3 (gamma) -3.02
DDX49 DEAD (Asp-Glu-Ala-Asp) box polypeptide 49 -2.89 *
EIF2S1 Eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa -2.88
KIFC1 Kinesin family member C1 -2.88 *
FLJ13910 Hypothetical protein FLJ13910 -2.85
APEX1 APEX nuclease (multifunctional DNA repair enzyme) 1 -2.83
COPB Coatomer protein complex, subunit beta -2.83
CDC25B Cell division cycle 25B -2.81 *
TMED2 transmembrane emp24 domain trafficking protein 2 -2.73
AHCYL1 S-adenosylhomocysteine hydrolase-like 1 -2.71 *
RAD23A RAD23 homolog A (S. cerevisiae) -2.70 *
HMGB2 High-mobility group box 2 -2.67
TRIM28 Tripartite motif-containing 28 -2.64 *
ENO1 Enolase 1, (alpha) -2.62 *
MRPL3 Mitochondrial ribosomal protein L3 -2.61 *
MARK2 MAP/microtubule affinity-regulating kinase 2 -2.61 *
DDX1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 -2.59 *
KIF22 Kinesin family member 22 -2.57
MLL myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) 2.57 *
YWHAE Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein 2.58
DUSP16 Dual specificity phosphatase 16 2.62 *
EZH1 Enhancer of zeste homolog 1 (Drosophila) 2.63 *
NCAM1 Neural cell adhesion molecule 1 2.63 *
MAP2K4 Mitogen-activated protein kinase kinase 4 2.64
ELAVL4 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu antigen D) 2.65 *
RBMS3 RNA binding motif, single stranded interacting protein 2.65 *
PXK PX domain containing serine/threonine kinase 2.66 *
PMSCL2 Exosome component 10 2.67 *
NTRK1 Neurotrophic tyrosine kinase, receptor, type 1 2.67 *
DOCK4 Dedicator of cytokinesis 4 2.70 *
AB051522 DIX domain containing 1 2.70 *
RAB2 RAB2, member RAS oncogene family 2.70 *
FOXP1 Forkhead box P1 2.74 *
GPS2 G protein pathway suppressor 2 2.79 *
MLL5 Myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax homolog, Drosophila) 2.82
DLG4 Discs, large homolog 4 (Drosophila) 2.84 *
VAMP2 Vesicle-associated membrane protein 2 (synaptobrevin 2) 2.85
NXPH1 Neurexophilin 1 2.89 *
ATP6V1A ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A 2.91
ZNF218 zinc finger protein 218 2.93
FLJ13110 Receptor accessory protein 1 2.94
CDK5R1 Cyclin-dependent kinase 5, regulatory subunit 1 (p35) 2.96 *
NCOA7 nuclear receptor coactivator 7 2.96 *
FLJ11730 Chromosome 1 open reading frame 149 3.04 *
MARCKS Myristoylated alanine-rich protein kinase C substrate 3.06 *
CLSTN3 Calsyntenin 3 3.08BMC Cancer 2007, 7:89 http://www.biomedcentral.com/1471-2407/7/89
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other samples: S114 and S076. From the sample dendro-
gram and the heatmap, three groups can be derived for all
remaining samples (from left to right): S091-S078, S108-
S080, S81-S90. The second group (S108-S080) mainly
contains patients with unfavourable outcome (six out of
eight), whereas the two other groups contain mainly
patients with favourable outcome (11 of 13). Thus, most
of the samples with similar clinical outcome are grouped
together, with a better grouping resulting from the data of
Oberthuer et al. Furthermore, the set of differentially
expressed genes can also be divided into two groups
according to their expression, one group shows low
expression in tumours with favourable outcome and high
expression in patients with an unfavourable outcome
while the other group shows inverted expression behav-
iour. The gene dendrograms of the heatmaps in figure 1A
and 1B both show a top level split that yields two roughly
equal-sized groups of 32 and 40 genes (Fig. 1A) or 30 and
42 genes (Fig. 1B), respectively. The set of genes in these
two groups are very similar in the two heatmaps for the
different studies, as only two genes (TMED2 and MARK2)
are grouped differently in the respective other study. Thus,
the set of 72 can be divided into two groups in each of
which genes show a highly consistant gene expression
behaviour.
By generating further colour maps for the expression of
the selected genes in MYCN  amplified stage 3 or 4
tumours and MYCN non amplified tumours with stages 1,
2, 4s of both studies (Fig. 2A,B), it was observed that the
expression pattern of the genes selected by meta-analysis
of intermediate risk neuroblastoma explicitly differs in the
most aggressive tumours compared to tumours with very
good prognosis. The full set of tumours from both studies
is shown in Additional Files 2 and 3. The tumours with
clearly defined prognosis show similar gene expression
patterns for the set of 72 differentially expressed genes as
the investigated tumour subgroup. These results suggest
that all MYCN  non-amplified tumours with advanced
stage (3 or 4) can be distinguished into just two biological
subtypes with contrasting clinical outcome according to
the expression profile of the 72 differentially expressed
genes. Moreover, expression of these genes also seems to
be a marker for tumour aggressiveness in other tumour
subgroups.
Clinical courses observed in non-amplified advanced stage 
patients with differing gene-expression patterns
In the data set of Oberthuer et al., seven patients that were
alive five years after diagnosis were clustered together with
those patients that had succumbed to disease (Fig. 1A).
Three of them had experienced an event, two of them even
had been treated with intensive salvage therapy, but all are
currently in complete or incomplete remission. Opposed
to that, three patients were documented to have experi-
enced an event within the subset of patients that were
clustered together as being alive five years after diagnosis.
In all these patients, local tumour progression was diag-
nosed but either surgical intervention revealed matura-
tion of the tissue or medium-dose chemotherapy resulted
in event-free survival since then. Thus, a different quality
of events was observed in those patients whose gene-
expression profile resembles that of patients who suc-
cumbed to disease, as opposed to those events that were
observed in patients whose gene-expression pattern
matched long-term event-free survivors. For the data set of
Ohira et al. (Fig. 1B) no detailed information about clini-
cal history of investigated patients was available.
Biological roles of the differentially expressed genes
Using the set of 72 significant genes for a hierarchical clus-
tering of MYCN  amplified stage 3 or 4 tumours and
MYCN non-amplified tumours with stages 1, 2, 4s, both
prognosis groups are clearly separated (Fig. 2). Therefore,
the expression of these 72 genes seems to be of general
importance for distinction of prognosis groups in neurob-
lastoma tumours.
In the group of genes that shows high expression in
tumours with favourable outcome, genes related to cell
CAMTA1 Calmodulin binding transcription activator 1 3.10
SCN3B sodium channel, voltage-gated, type III, beta 3.11 *
PTN Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1) 3.14
EPS15 Epidermal growth factor receptor pathway substrate 15 3.26
BRUNOL4 Bruno-like 4, RNA binding protein (Drosophila) 3.26
DCAMKL1 Doublecortin and CaM kinase-like 1 3.30
ALS2CL ALS2 C-terminal like 3.38
LOC284244 Hypothetical protein LOC284244 3.41
RAPGEF6 Rap guanine nucleotide exchange factor (GEF) 6 3.42
PKIB Protein kinase (cAMP-dependent, catalytic) inhibitor beta 3.50
LOC116236 Hypothetical protein LOC116236 3.89
FYN FYN oncogene related to SRC, FGR, YES 3.96
Column 'only found in M.A.': Those genes are marked that were exclusively identified by meta-analysis. A negative z-score indicates down-regulation of a gene in 
tumors with a favourable prognosis relative to the expression in tumors with unfavourable prognosis.
Table 2: List of differentially expressed genes. (Continued)BMC Cancer 2007, 7:89 http://www.biomedcentral.com/1471-2407/7/89
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Hierarchical clustering of the expression data for the significant genes in advanced stage MYCN amplified tumors versus low  stage non-amplified tumors Figure 2
Hierarchical clustering of the expression data for the significant genes in advanced stage MYCN amplified 
tumors versus low stage non-amplified tumors. (A) Oligonucleotide data. (B) cDNA data. The colored bars at the top of 
the figure denote the values of the following clinical variables: Status: black – unfavourable outcome, grey – favourable out-
come; Age (at diagnosis): black – older than one year, grey – younger than one year.
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Hierarchical clustering of the expression data for the significant genes in advanced stage MYCN non-amplified tumors Figure 1
Hierarchical clustering of the expression data for the significant genes in advanced stage MYCN non-amplified 
tumors. (A) Oligonucleotide data. (B) cDNA data. The colored bars at the top of the figure denote the values of the following 
clinical variables: Status: black – unfavourable outcome, grey – favourable outcome; Age (at diagnosis): black – older than one 
year, grey – younger than one year; Stage: black – INSS stage 4, grey – INSS stage 3.
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differentiation (FYN, NTRK1) and neuronal development
(DCAMKL1) can be found. Among the significant genes
that show a high expression in tumours with unfavoura-
ble outcome, cell cycle associated genes can be found
(E2F1, CCNA2, CCNB1, KIFC1).
To further characterize which biological functions are
defined by these genes, we explored the GO terms associ-
ated with the significant genes in order to identify the bio-
logical roles represented by these genes. We ranked the
GO terms associated with the selected genes in our meta-
analysis by using the p-values generated in a GO based
gene set enrichment analysis as implemented in the GOs-
tat tool. The most highly ranked annotation terms are
listed in Table 3. Among these, GO terms can be found for
which the associated genes all show higher expression in
tumours with unfavourable outcome (e.g. cell cycle and
DNA maintenance associated terms), as well as terms for
which the associated genes show higher expression in
tumours with favourable outcome (e.g. negative regula-
tion of MAPK activity). The genes associated with the
given GO terms are listed in Additional File 4.
Classification analysis
According to the German neuroblastoma risk stratifica-
tion protocol, patients with non-MYCN  amplified
advanced stage 3 or 4 disease may be grouped into either
the low-, the intermediate- or the high-risk group,
Table 4: Performance of different markers for outcome prediction on the independent test set.
Accuracy Sensitivity Specificity
Microarray classifier 0.77, [0.66;0.85], (23/30) 0.86, [0.62;0.96], (6/7) 0.74, [0.61;0.84], (17/23)
Age 0.53, [0.42;0.65], (16/30) 1.0, [0.81;1.0], (7/7) 0.39, [0.27;0.52], (9/23)
Stage 0.60, [0.48;0.71], (18/30) 1.0, [0.81;1.0], (7/7) 0.48, [0.35;0.61], (11/23)
Age + Stage 0.70, [0.58;0.79], (21/30) 1.0, [0.81;1.0], (7/7) 0.61, [0.48;0.73], (14/23)
The figures in brackets denote 95% confidence intervals and absolute number of cases. For prediction of outcome by age at diagnosis, patients older 
than one year were predicted with unfavourable outcome. For prediction by stage, patients with stage 3 were predicted with favourable outcome 
and patients with stage 4 were predicted with unfavourable outcome. For the combination of the markers age and stage, only stage 4 patients older 
than one year at dignosis were predicted with unfavourable outcome. Sensitivity/Specificity is rate of correctly predicted patients with unfavourable/
favourable outcome.
Table 3: Enriched GO terms in the category "Biological Process" among the significantly differentially expressed genes.
GO term Expression Count {55} Total {857} p-value Corrected p
base-excision repair - 2 2 0.004 0.307
regulation of kinase activity + 5 19 0.005 0.307
regulation of protein kinase activity + 5 19 0.005 0.307
regulation of transferase activity + 5 20 0.007 0.307
negative regulation of transferase activity + 3 7 0.007 0.307
negative regulation of protein kinase activity + 3 7 0.007 0.307
negative regulation of enzyme activity + 3 8 0.011 0.361
regulation of enzyme activity + 5 25 0.018 0.361
response to DNA damage stimulus - 4 17 0.019 0.361
response to endogenous stimulus - 4 17 0.019 0.361
MAPKKK cascade + 3 10 0.022 0.361
one-carbon compound metabolism - 2 4 0.022 0.361
negative regulation of MAPK activity + 2 4 0.022 0.361
inactivation of MAPK activity + 2 4 0.022 0.361
M phase of mitotic cell cycle - 4 18 0.024 0.361
phosphorus metabolism + 9 68 0.033 0.361
phosphate metabolism + 9 68 0.033 0.361
M phase - 4 20 0.034 0.361
regulation of cyclin dependent protein kinase activity - 2 5 0.036 0.361
glycolysis - 2 5 0.036 0.361
Wnt receptor signaling pathway + 2 5 0.036 0.361
oxidative phosphorylation * 2 5 0.036 0.361
Expression: expression of associated genes in tumors with a favourable prognosis relative to the expression in tumors with unfavourable prognosis; 
+: up-regulation; -: down-regulation; *: genes show oppositional expression.
Count: number of significant genes associated with given GO term. Total: number of genes in analysis associated with given GO term. The numbers 
in curly brackets denote the number of genes that could be mapped to GO. Corrected p-values were calculated according to Benjamini and 
Hochberg as implemented in GOstat.BMC Cancer 2007, 7:89 http://www.biomedcentral.com/1471-2407/7/89
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depending on their age at diagnosis, or an alteration of the
short arm of chromosome 1 (del1p). Therefore, the inves-
tigated subgroup of neuroblastoma patients would greatly
profit from an improved risk estimation. Independently
to the analysis described above, we generated a predictive
model for patient outcome using the method of nearest
shrunken centroids classification [18] based on data of
both studies. For this, 36 patients were selected from both
studies as a training set, the remainig patients were used as
a independent test set. The resulting predictive model,
achieved a predictive accuracy of 77% for neuroblastoma
in stage 3 or 4 without MYCN amplification in the inde-
pendent test set (Table 4), using the expression values of
256 genes. Inferior predictive accuracies were achieved
when the samples were classified by the clinical parame-
ters age and stage, although no statistical significance of
the difference in predictive accuracy between the best clin-
ical parameter (a combination of age and stage) and the
microarray based classification was observed, as the 95%
confidence intervals were overlapping. Application of the
microarray based classifier also resulted in good perform-
ance in terms of both sensitivity and specificity, indicating
the feasibility of generating and applying a predictive
model of outcome based on data of different gene expres-
sion profiling studies. The overlap of the list of 256 genes
used for classification with the list of 72 genes identified
by meta analysis and the list of 144 genes used for classi-
fication in [8] is shown in Additional File 5.
Discussion
In this study, we combined gene expression data from two
different studies to investigate the differences in gene
expression for advanced stage MYCN  non-amplified
tumours with contrasting outcome at five years after ini-
tial diagnosis.
Our results suggest that this subgroup of tumours can be
distinguished into two biological subtypes showing dis-
tinct gene expression profiles that are associated with con-
trasting clinical outcomes. The expression of the genes
that are differentially expressed between these two sub-
types may represent a general indicator of neuroblastoma
aggressiveness, since corresponding expression behaviour
can be observed in low stage MYCN  non-amplified
tumours as well as advanced stage MYCN  amplified
tumours.
Instead of simply comparing lists of differentially
expressed genes obtained on single study data or combin-
ing p-values calculated for each single study [19], we
applied a method of meta-analysis on the gene expression
data that is based on a well established statistical frame-
work and comprises modelling of study-to-study differ-
ences [10]. Unfortunately, the combination of gene
expression data from different studies has the disadvan-
tage that only genes common to all microarray platforms
can be used. As the reliability of the probe mapping is cru-
cial for a cross-platform analysis, we applied a stringent
sequence based mapping of the probes of different micro-
array platforms in order to avoid inappropriate mapping
of the probes. The combination of data from different
studies for our analysis resulted in a large number of
included expression profiles for the investigated subset of
patients although a stringent selection criterion of a fol-
low up of 5 years was applied. This clearly led to a higher
statistical power of our analysis in comparison to single
study based results, since of the 72 significantly differen-
tially expressed genes, 34 genes were found exclusively in
the meta-analysis of both sets.
Among the significantly differentially expressed genes are
some that are known in the context of neuroblastoma
research. Our results confirm observations made for these
genes as described earlier in literature. High expression of
NTRK1 is present in neuroblastomas with favourable bio-
logical features and highly correlated with patient survival
[20]. High expression of FYN and high FYN kinase activity
are restricted to low-stage tumours [21]. PTN is highly
expressed in favourable neuroblastomas, whereas it is
expressed at a significantly lower level in advanced
tumours [22]. Low CAMTA1 expression is associated with
poor outcome [23]. NCAM expression seems to enhance
the malignancy of neuroblastoma cells and their tendency
to metastasise [24]. High HuD (ELAVL4) mRNA levels
may predict a clinically favourable outcome [25]. The fact
that some of these genes were exclusively detected by the
meta-analysis (Table 2) underlines the benefit of cross-
study analyses for investigation of tumour subgroups.
Interestingly, the 72 genes found to be significant for the
investigated subgroup of neuroblastoma tumours also
show a distinct differential expression in other prognostic
subgroups and may thus be used as a general prognostic
marker for neuroblastoma patients. Moreover, this result
suggests that, although for neuroblastoma tumours sev-
eral different clinical stages and risk groups are defined,
on the level of gene expression they seem to comprise
only two distinct biological entities associated with
adverse patient outcome.
The GO based gene set enrichment analysis of the GO
terms associated with the selected genes in our meta-anal-
ysis did not show that any GO term is overrepresented
with high statistical significance. However, the p-values
calculated in the gene set enrichment analysis provide a
useful ranking of the GO annotation terms that we used
to select the genes shown in table 3 for characterization of
the biological functions represented by the selected genes.
Among the GO annotation terms associated with the
genes selected in our meta-analysis, the GO-based gene set
enrichment analysis highly ranked the cell cycle associ-BMC Cancer 2007, 7:89 http://www.biomedcentral.com/1471-2407/7/89
Page 9 of 11
(page number not for citation purposes)
ated GO terms. The up-regulation of the expression of cell
cycle genes in aggressive neuroblastoma tumours was
already observed by Krasnoselsky et al. [26] in a compari-
son of tumours of different stages and MYCN amplifica-
tion status, where patient outcome was not regarded. In
addition to the cell cycle genes, gene set enrichment anal-
ysis of the GO terms associated with the significant genes
resulted in high rankings of three other GO terms known
to be affected in tumorigenesis: DNA damage response,
negative regulation of MAPK activity [27] and Wnt recep-
tor signalling pathway [28]. For DNA-damage response
genes, higher expression can be observed in tumours with
a unfavourable outcome than in tumours with favourable
outcome. This effect can also be seen in other tumour
entities like prostate cancer. For the gene APEX1, gene
expression data is available in the gene expression data
repository Oncomine [29] that shows increasing expres-
sion according to tumour malignancy (Additional File 1).
This effect might be caused by accumulated genetic abber-
ations in tumours with unfavourable outcome which trig-
ger the activity of DNA-damage response genes.
While interpreting the analysis of gene expression for
non-amplified advanced stage neuroblastoma tumours
with regard to patient outcome, the influence of the ther-
apy that all these patients have received has to be taken
into account, as differences of the gene expression profiles
with regard to patient outcome may not only reflect
tumour malignancy but also tumour responsiveness to
the therapy.
Although only a small number of patients were available
for generation and assessment of a predictive model, out-
come prediction based on data of both studies (only genes
common to both platforms) yielded good results. Both
patients with favourable and unfavourable outcome were
classified with good results as indicated by a balanced
ratio of sensitivity and specificity. This shows the potential
of the approach to use data of different gene expression
studies to derive predictive models for patient subgroups
where gene expression data is rare. However, for stable
and compact (in terms of the number of used genes) pre-
dictive models, a larger total number of samples is needed
[30] which could be realised by combination of future
gene expression profiling studies with the approach used
here.
Conclusion
In conclusion, cross-study analysis of gene expression
data enables to detect consistent effects of gene expression
based on completely independent data sets. The increase
of statistical power through cross-study analysis is espe-
cially beneficial for the analysis of important patient sub-
groups for which gene expression data is rare. The
presented results characterise a patient outcome specific
set of differentially expressed genes in MYCN non-ampli-
fied advanced stage tumours. The resemblance of the
expression of these genes in the investigated subgroup
and in tumours with clearly defined (and diverging) out-
come suggests that neuroblastomas comprise only two
distinct biological subtypes associated with contrasting
patient outcome.
Further investigations are needed to extend and validate
these findings, a process in which the combination of
future gene expression profiling studies which are larger
both with respect to the investigated patients and probes
on the utilised microarray platforms (thus yielding a large
intersection of common probes), could play an important
role.
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